Preferred Stock Offering Details: |
CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 55,000 shares of its Series N-2 Preferred Stock, offered at a price to the public of $1,000 per share of Series N-2 Preferred Stock (the "Offering"). Each share of Series N-2 Preferred Stock is convertible at the option of the holder, at any time subject to certain limitations, into shares of our common stock at a conversion price of $1.10 per share of common stock, for a total of approximately 50,000,000 shares of common stock. |